1. Home
  2. NVAX vs MSDL Comparison

NVAX vs MSDL Comparison

Compare NVAX & MSDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NVAX
  • MSDL
  • Stock Information
  • Founded
  • NVAX 1987
  • MSDL 2019
  • Country
  • NVAX United States
  • MSDL United States
  • Employees
  • NVAX N/A
  • MSDL N/A
  • Industry
  • NVAX Biotechnology: Biological Products (No Diagnostic Substances)
  • MSDL
  • Sector
  • NVAX Health Care
  • MSDL
  • Exchange
  • NVAX Nasdaq
  • MSDL NYSE
  • Market Cap
  • NVAX 2.0B
  • MSDL 1.8B
  • IPO Year
  • NVAX 1995
  • MSDL N/A
  • Fundamental
  • Price
  • NVAX $9.76
  • MSDL $19.91
  • Analyst Decision
  • NVAX Buy
  • MSDL Buy
  • Analyst Count
  • NVAX 6
  • MSDL 7
  • Target Price
  • NVAX $17.83
  • MSDL $21.67
  • AVG Volume (30 Days)
  • NVAX 7.2M
  • MSDL 407.4K
  • Earning Date
  • NVAX 11-07-2024
  • MSDL 01-01-0001
  • Dividend Yield
  • NVAX N/A
  • MSDL 7.50%
  • EPS Growth
  • NVAX N/A
  • MSDL N/A
  • EPS
  • NVAX N/A
  • MSDL N/A
  • Revenue
  • NVAX $987,667,000.00
  • MSDL N/A
  • Revenue This Year
  • NVAX N/A
  • MSDL $1,597.39
  • Revenue Next Year
  • NVAX N/A
  • MSDL $14.28
  • P/E Ratio
  • NVAX N/A
  • MSDL N/A
  • Revenue Growth
  • NVAX N/A
  • MSDL N/A
  • 52 Week Low
  • NVAX $3.53
  • MSDL $19.05
  • 52 Week High
  • NVAX $23.86
  • MSDL $24.18
  • Technical
  • Relative Strength Index (RSI)
  • NVAX 36.20
  • MSDL 52.37
  • Support Level
  • NVAX $9.52
  • MSDL $19.48
  • Resistance Level
  • NVAX $10.63
  • MSDL $20.39
  • Average True Range (ATR)
  • NVAX 0.57
  • MSDL 0.34
  • MACD
  • NVAX -0.12
  • MSDL 0.02
  • Stochastic Oscillator
  • NVAX 9.97
  • MSDL 69.06

About NVAX Novavax Inc.

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The Company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from Europe.

About MSDL MORGAN STANLEY DIRECT LENDING FUND

Morgan Stanley Direct Lending Fund is a fund whose investment objective is to achieve attractive risk-adjusted returns via current income and, to a lesser extent, capital appreciation by investing predominantly in directly originated senior secured term loans issued by U.S. middle-market companies backed by private equity sponsors. It invests predominantly in directly originated senior secured term loans including first lien senior secured term loans including unitranche loans and second lien senior secured term loans, with the balance of the investments expected to be in higher-yielding assets such as mezzanine debt, unsecured debt, equity investments and other opportunistic asset purchases.

Share on Social Networks: